{"nctId":"NCT00333775","briefTitle":"A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer","startDateStruct":{"date":"2006-03"},"conditions":["Breast Cancer"],"count":736,"armGroups":[{"label":"Docetaxel 100 mg/m^2 plus placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Docetaxel","Drug: Placebo to bevacizumab"]},{"label":"Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Docetaxel","Drug: Bevacizumab"]},{"label":"Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Docetaxel","Drug: Bevacizumab"]}],"interventions":[{"name":"Docetaxel","otherNames":[]},{"name":"Placebo to bevacizumab","otherNames":[]},{"name":"Bevacizumab","otherNames":["Avastin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Female patients ≥ 18 years of age.\n* Human epidermal growth factor receptor 2 (HER2)-negative cancer of the breast with locally recurrent or metastatic disease, suitable for chemotherapy.\n* No adjuvant chemotherapy within 6 months before randomization, and no taxane-based chemotherapy within 12 months before randomization.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n\nExclusion criteria:\n\n* Previous chemotherapy for metastatic or locally recurrent breast cancer.\n* Radiotherapy for treatment of metastatic disease.\n* Other primary tumors within last 5 years, except for controlled limited basal cell or squamous cancer of the skin, or cancer in situ of the cervix.\n* Spinal cord compression or brain metastases.\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization.\n* Inadequate bone marrow, liver, or renal function.\n* Uncontrolled hypertension.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival","description":"Progression-free survival was evaluated using Response Evaluation Criteria In Solid Tumors (RECIST 1.0). Progression-free survival was defined as the time from randomization to the time of the first documented disease progression or death, whichever occurred first. Disease progression was defined as ≥ 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions, or appearance of new lesion(s).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"8.7","spread":null},{"groupId":"OG002","value":"8.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Complete Response or a Partial Response","description":"Responses were evaluated using the Response Evaluation Criteria in Solid Tumors. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.5","spread":null},{"groupId":"OG001","value":"52.2","spread":null},{"groupId":"OG002","value":"62.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of response was defined as the time from the first documented complete response or partial response to disease progression or death. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were evaluated using the Response Evaluation Criteria in Solid Tumors.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":null},{"groupId":"OG001","value":"7.2","spread":null},{"groupId":"OG002","value":"7.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Treatment Failure","description":"Time to treatment failure was defined as time from randomization to the date of disease progression, death, or withdrawal of treatment due to an adverse event, withdrawal of informed consent, insufficient therapeutic response, refusal of treatment/failure to co-operate, or failure to return, whichever occurred first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"7.0","spread":null},{"groupId":"OG002","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival was defined as the time from randomization to death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":82,"n":217},"commonTop":["Alopecia","Diarrhoea","Nausea","Nail disorder","Fatigue"]}}}